Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Destiny Pharma is a UK-based clinical stage developer of medicines for the prevention and treatment of infections caused by drug-resistant bacteria. Destiny has confirmed that its lead candidate, topical antimicrobial XF-73, has been granted FDA Fast Track Designation in the new FDA-backed indication - prevention of post-surgical staphylococcal infection. Following the recent Investigational New Drug (IND) opening, XF-73 is due to enter Phase IIb studies this year, positioning it as a potential ...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
​Motif Bio is a clinical stage biopharma company specialising in developing novel antibiotics to combat life-threatening diseases caused by multi-drug resistant bacteria. Recent QIDP status for iclaprim in both serious skin and bacterial pneumonia indication is very significant, meaning that it benefits from a fast-track approval process and receives an extra 5 years of marketing exclusivity in the US (from the date of approval - H1'18 forecast) under Hatch-Waxman legislation (making a total o...
Motif Bio PLC (MTFB) is a drug discovery and development company targeting new antibiotic solutions. Modern medicine is under threat from antibiotic resistance, particularly for hospital-acquired infections (HAI). MTFB has an opportunity to help strengthen the physician's toolbox for antibiotic-resistant bacteria. MTFB recently raised £2.8m listing on AIM to support steps towards a Phase 3 programme of its recently acquired novel antibiotic, iclaprim, in two significant HAI indication areas. Th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.